New drug tested for rare blood disorder in china
NCT ID NCT06287567
First seen Jan 05, 2026 · Last updated Apr 20, 2026 · Updated 18 times
Summary
This study tested whether the drug lusutrombopag could safely raise platelet counts in Chinese adults with chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The trial involved 17 participants who hadn't responded well to standard first treatments. Researchers measured whether platelet counts improved after 4 and 12 weeks of taking the medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.